Skip to content

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

News

Select Year
Clinical Trials
Search …

April 7, 2014

Media Advisory – Oncolytics Biotech® Inc. to Participate in 13th Annual Needham Healthcare Conference

March 13, 2014

Oncolytics Biotech® Inc. Announces 2013 Year End Results

March 4, 2014

MEDIA ADVISORY – Oncolytics Biotech® Inc. to Participate in the 34th Annual Cowen and Company Healthcare Conference

February 27, 2014

Oncolytics Biotech® Inc. Announces Initial US$1.0 Million Investment and Up to US$25.0 Million Common Share Purchase Agreement with Lincoln Park Capital Fund, LLC

February 25, 2014

Media Advisory – Oncolytics Biotech® Inc. to Participate in 2014 RBC Capital Markets Global Healthcare Conference

December 3, 2013

Oncolytics Biotech® Inc. to Present at the 25th Annual Piper Jaffray Healthcare Conference

November 21, 2013

Oncolytics Biotech® Inc. Announces Positive Top-Line Data from REO 018 Randomized Study of REOLYSIN® in Head and Neck Cancers

November 7, 2013

Oncolytics Biotech® Inc. Announces Third Quarter 2013 Results

October 28, 2013

Oncolytics Biotech® Inc. Collaborators Present Positive Data Correlating Specific Biomarkers with Survival in NSCLC Patients Treated with REOLYSIN®, Carboplatin and Paclitaxel

October 22, 2013

Oncolytics Biotech® Inc. Announces Progression Free Survival Data for Phase 2 Study of REOLYSIN® in Squamous Cell Lung Cancer

Page 43 of 69

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.ca

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

About Us
Leadership
Scientific Advisors
Careers
Contact

Science

Our Science
Pipeline
Publications

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Sitemap Manage Consent

Copyright © 2025 Oncolytics Biotech Inc.